Piramal Pharma Limited Max Pain Analysis
What is Max Pain?
Max Pain theory states the underlying gravitates toward the strike where option writers face minimum collective loss at expiry. For PPLPHARMA, that strike is ₹148. Spot at ₹151.19 is 2.5% above max pain — possible downward gravitational pull into expiry.
Max Pain Level
Piramal Pharma Limited’s max pain sits at ₹147.5, the strike where option sellers incur the least total loss at expiry. This level often acts as a magnet in the final days, as gamma effects and dealer hedging intensify around concentrated open interest.
Spot vs Max Pain Gap
The spot price at ₹151.19 trades 2.5% above the max pain point, creating upward pressure from in-the-money call liabilities. This gap suggests a potential pull toward ₹147.5 unless strong bullish momentum sustains spot levels.
Shift Signal
The max pain level is unchanged from yesterday, indicating stable writer positioning across strikes. Lack of shift reflects balanced near-term sentiment among sellers, with no aggressive adjustments in premium distribution.
Expiry Bias
With 7 days to expiry, a mild downward drift toward ₹147.5 is expected, supported by the spot-pain gap and seller behavior. The pull strengthens if the spot enters the ₹147.5–150 zone, especially within the final 5 days when gamma effects dominate.
Trader Note
With more than 5 days left, avoid premium decay strategies; wait for tighter expiry proximity to exploit time decay near ₹147.5 or the secondary node at ₹150.
Data as of 2026-04-21